Literature DB >> 19785005

Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody.

K Reed Clark1, Scott T R Walsh.   

Abstract

We present the crystal structure determination of an anti-HIV-1 gp120 single-chain variable fragment antibody variant, 3B3, at 2.5 A resolution. This 3B3 variant was derived from the b12 antibody, using phage display and site-directed mutagenesis of the variable heavy chain (V(H)) complementary-determining regions (CDRs). 3B3 exhibits enhanced binding affinity and neutralization activity against several cross-clade primary isolates of HIV-1 by interaction with the recessed CD4-binding site on the gp120 envelope protein. Comparison with the structures of the unbound and bound forms of b12, the 3B3 structure closely resembles these structures with minimal differences with two notable exceptions. First, there is a reorientation of the CDR-H3 of the V(H) domain where the primary sequences evolved from b12 to 3B3. The structural changes in CDR-H3 of 3B3, in light of the b12-gp120 complex structure, allow for positioning an additional Trp side chain in the binding interface with gp120. Finally, the second region of structural change involves two peptide bond flips in CDR-L3 of the variable light (V(L)) domain triggered by a point mutation in CDR-H3 of Q100eY resulting in changes in the intramolecular hydrogen bonding patterning between the V(L) and V(H) domains. Thus, the enhanced binding affinities and neutralization capabilities of 3B3 relative to b12 probably result from higher hydrophobic driving potential by burying more aromatic residues at the 3B3-gp120 interface and by indirect stabilization of intramolecular contacts of the core framework residues between the V(L) and V(H) domains possibly through more favorable entropic effect through the expulsion of water.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19785005      PMCID: PMC2821263          DOI: 10.1002/pro.255

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  39 in total

1.  Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.

Authors:  Ramalakshmi Darbha; Sanjay Phogat; Aran F Labrijn; Yuuei Shu; Yijun Gu; Michelle Andrykovitch; Mei-Yun Zhang; Ralph Pantophlet; Loic Martin; Claudio Vita; Dennis R Burton; Dimiter S Dimitrov; Xinhua Ji
Journal:  Biochemistry       Date:  2004-02-17       Impact factor: 3.162

2.  Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.

Authors:  Philip R Johnson; Bruce C Schnepp; Mary J Connell; Daniela Rohne; Suzanne Robinson; Georgia R Krivulka; Carol I Lord; Rebekah Zinn; David C Montefiori; Norman L Letvin; K Reed Clark
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range.

Authors:  W P Yang; K Green; S Pinz-Sweeney; A T Briones; D R Burton; C F Barbas
Journal:  J Mol Biol       Date:  1995-12-01       Impact factor: 5.469

4.  In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.

Authors:  C F Barbas; D Hu; N Dunlop; L Sawyer; D Cababa; R M Hendry; P L Nara; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

5.  Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

Authors:  Michael B Zwick; Paul W H I Parren; Erica O Saphire; Sarah Church; Meng Wang; Jamie K Scott; Philip E Dawson; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

6.  Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.

Authors:  Anne D Lewis; Ruju Chen; David C Montefiori; Philip R Johnson; K Reed Clark
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  How to measure and predict the molar absorption coefficient of a protein.

Authors:  C N Pace; F Vajdos; L Fee; G Grimsley; T Gray
Journal:  Protein Sci       Date:  1995-11       Impact factor: 6.725

8.  Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies.

Authors:  Erica Ollmann Saphire; Marinieve Montero; Alfredo Menendez; Nienke E van Houten; Melita B Irving; Ralph Pantophlet; Michael B Zwick; Paul W H I Parren; Dennis R Burton; Jamie K Scott; Ian A Wilson
Journal:  J Mol Biol       Date:  2007-01-27       Impact factor: 5.469

9.  Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Authors:  James M Binley; Terri Wrin; Bette Korber; Michael B Zwick; Meng Wang; Colombe Chappey; Gabriela Stiegler; Renate Kunert; Susan Zolla-Pazner; Hermann Katinger; Christos J Petropoulos; Dennis R Burton
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  5 in total

1.  Bioinformatics-led design of single-chain antibody molecules targeting DNA sequences for retinoblastoma.

Authors:  Guo-Gang Shang; Jian-Hua Zhang; Yong-Gang Lü; Jun Yun
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

2.  Specific fluorine labeling of the HyHEL10 antibody affects antigen binding and dynamics.

Authors:  Mauro Acchione; Yi-Chien Lee; Morgan E DeSantis; Claudia A Lipschultz; Alexander Wlodawer; Mi Li; Aranganathan Shanmuganathan; Richard L Walter; Sandra Smith-Gill; Joseph J Barchi
Journal:  Biochemistry       Date:  2012-07-16       Impact factor: 3.162

3.  Analysis of the relationship between end-to-end distance and activity of single-chain antibody against colorectal carcinoma.

Authors:  Jianhua Zhang; Shanhong Liu; Zhigang Shang; Li Shi; Jun Yun
Journal:  Theor Biol Med Model       Date:  2012-08-22       Impact factor: 2.432

4.  Rational library design by functional CDR resampling.

Authors:  Qi Zhao; Diane Buhr; Courtney Gunter; Jenny Frenette; Mary Ferguson; Eric Sanford; Erika Holland; Chitra Rajagopal; Melissa Batonick; Margaret M Kiss; Michael P Weiner
Journal:  N Biotechnol       Date:  2017-12-11       Impact factor: 5.079

5.  Kappa chain maturation helps drive rapid development of an infant HIV-1 broadly neutralizing antibody lineage.

Authors:  Cassandra A Simonich; Laura Doepker; Duncan Ralph; James A Williams; Amrit Dhar; Zak Yaffe; Lauren Gentles; Christopher T Small; Brian Oliver; Vladimir Vigdorovich; Vidya Mangala Prasad; Ruth Nduati; D Noah Sather; Kelly K Lee; Frederick A Matsen Iv; Julie Overbaugh
Journal:  Nat Commun       Date:  2019-05-16       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.